PDCD1 and cancer: Immune checkpoint blockade therapy, which includes the inhibition of programmed cell death 1 (PD-1) or ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen-4 (CTLA-4), helps to extend various cancer lineages survival.